Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD) ; volume:10 ; number:1 ; day:28 ; month:6 ; year:2010 ; pages:1-6 ; date:12.2010
BMC gastroenterology ; 10, Heft 1 (28.6.2010), 1-6, 12.2010
- Urheber
-
Raszeja-Wyszomirska, Joanna
- Beteiligte Personen und Organisationen
-
Szymanik, Barbara
Ławniczak, Małgorzata
Kajor, Maciej
Chwist, Alina
Milkiewicz, Piotr
Hartleb, Marek
SpringerLink (Online service)
- DOI
-
10.1186/1471-230X-10-67
- URN
-
urn:nbn:de:1111-201607153960
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.01.2025, 08:31 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Raszeja-Wyszomirska, Joanna
- Szymanik, Barbara
- Ławniczak, Małgorzata
- Kajor, Maciej
- Chwist, Alina
- Milkiewicz, Piotr
- Hartleb, Marek
- SpringerLink (Online service)
Ähnliche Objekte (12)
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?